{
    "ticker": "LXEO",
    "name": "Lexeo Therapeutics, Inc.",
    "description": "Lexeo Therapeutics, Inc. is a biotechnology company focused on developing innovative gene therapies for the treatment of rare genetic diseases. Founded in 2018, Lexeo is at the forefront of advancing therapies that leverage the power of adeno-associated virus (AAV) technology. The company\u2019s mission is to transform the lives of patients suffering from serious conditions by providing effective and safe treatment options. Lexeo's pipeline includes therapies targeting diseases such as Duchenne muscular dystrophy (DMD) and other neuromuscular disorders. Through its commitment to scientific excellence and collaboration, Lexeo is working closely with leading academic institutions and researchers to push the boundaries of genetic medicine. The company is dedicated to addressing unmet medical needs and improving patient outcomes through cutting-edge research and development. With a strong emphasis on patient care and innovative science, Lexeo aims to be a leader in the gene therapy landscape, making significant strides towards a future where genetic diseases can be effectively managed or cured.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2018",
    "website": "https://www.lexeotx.com",
    "ceo": "Joseph R. B. Kunkel",
    "social_media": {
        "twitter": "https://twitter.com/LexeoTx",
        "linkedin": "https://www.linkedin.com/company/lexeo-therapeutics/"
    },
    "investor_relations": "https://www.lexeotx.com/investors",
    "key_executives": [
        {
            "name": "Joseph R. B. Kunkel",
            "position": "CEO"
        },
        {
            "name": "Tommy McNulty",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "LX1001",
                "LX2001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Lexeo Therapeutics, Inc. | Innovative Gene Therapies for Rare Diseases",
        "meta_description": "Learn about Lexeo Therapeutics, Inc., a biotechnology company focused on developing gene therapies for rare genetic diseases. Explore our innovative pipeline and commitment to patient care.",
        "keywords": [
            "Lexeo Therapeutics",
            "Gene Therapy",
            "Duchenne Muscular Dystrophy",
            "Rare Diseases",
            "Biotechnology",
            "Genetic Medicine"
        ]
    },
    "faq": [
        {
            "question": "What does Lexeo Therapeutics focus on?",
            "answer": "Lexeo Therapeutics focuses on developing innovative gene therapies for the treatment of rare genetic diseases."
        },
        {
            "question": "Who is the CEO of Lexeo Therapeutics?",
            "answer": "Joseph R. B. Kunkel is the CEO of Lexeo Therapeutics, Inc."
        },
        {
            "question": "Where is Lexeo Therapeutics headquartered?",
            "answer": "Lexeo Therapeutics is headquartered in New York, New York, USA."
        },
        {
            "question": "What are Lexeo's main products?",
            "answer": "Lexeo's main products include LX1001 and LX2001, which are gene therapies targeting rare genetic diseases."
        },
        {
            "question": "When was Lexeo Therapeutics founded?",
            "answer": "Lexeo Therapeutics was founded in 2018."
        }
    ],
    "competitors": [
        "AVDL",
        "SGEN",
        "CRSP",
        "EDIT"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "BMY",
        "GILD"
    ]
}